Back

Anxo signs South Korea drug license for $100 million market

Verifying
  • Anxo Pharmaceutical granted YS Life Science exclusive South Korean rights for its Elishu treatment.
  • The South Korean same-ingredient therapeutic market is valued at approximately $100 million.
  • YS will conduct bioequivalence testing, pursue registration and handle subsequent local sales.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Anxo signs South Korea drug license for $100 million market - CoinPost Terminal